Showing 1 - 5 results of 5 for search 'Frederik Flindt Kreiner', query time: 0.04s Refine Results
  1. 1
    The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

    The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice by Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, Peter Rossing, Thomas Idorn

    Published 2022-07-01
    Get full text
    Article
  2. 2
    The potential of glucagon-like peptide-1 receptor agonists in heart failure

    The potential of glucagon-like peptide-1 receptor agonists in heart failure by Frederik Flindt Kreiner, G. Kees Kornelis Hovingh, G. Kees Kornelis Hovingh, Bernt Johan von Scholten

    Published 2022-09-01
    Get full text
    Article
  3. 3
    Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

    Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study by Bendix Carstensen, Stephen C Bain, Hanan Amadid, Alice Clark, Liselotte Hyveled, Stephanie Seremetis, Frederik Flindt Kreiner

    Published 2023-05-01
    Get full text
    Article
  4. 4
    Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]

    Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mo... by Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

    Published 2024-11-01
    Get full text
    Article
  5. 5
    Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

    Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity by Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

    Published 2023-12-01
    Get full text
    Article

Search Tools: